drugset
Drugs / Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
last change Mar 2026 re-read 3 minutes ago

Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE

Vaccine

Developed for
colorectal adenocarcinoma · esophageal adenocarcinoma · gastric adenocarcinoma · gastroesophageal adenocarcinoma · pancreatic ductal adenocarcinoma · small intestine adenocarcinoma
Investigated by
Thomas Jefferson University

Trials 1

today NCT04111172 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT04111172 Nov 2020 → Mar 2026 overdue colorectal adenocarcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal adenocarcinoma +2 Thomas Jefferson University Active not recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE ClinicalTrials.gov intervention name — accepted as the source's own label NCT04111172 ↗
Modality Vaccine “Ad5.F35-hGCC-PADRE vaccine” NCT04111172 ↗
Route Intramuscular “Given as intramuscular injection” NCT04111172 ↗